Guo Wan-Liang, Geng Jia, Zhao Jun-Gang, Fang Fang, Huang Shun-Gen, Wang Jian
Department of Radiology, Children's Hospital of Soochow University, Suzhou, China.
Clinical Laboratory, the 3rd Hospital of Yulin, Yulin, China.
Braz J Med Biol Res. 2019;52(8):e8522. doi: 10.1590/1414-431X20198522. Epub 2019 Jul 29.
Pancreaticobiliary maljunction (PBM) is associated with high risk of epithelial atypical growth and malignant transformation of the bile duct or gallbladder. However, overall changes in genetic expression have not been examined in children with PBM. Genome-wide expression was analyzed using peripheral blood samples from 10 children with PBM and 15 pediatric controls. Differentially expressed genes (DEGs) were identified using microarray. Bioinformatics analysis was conducted using Gene Ontology and KEGG analyses. The top 5 in the up-regulated genes in PBM were verified with qRT-PCR. Receiver operator characteristic curve analysis was conducted to evaluate the predictive accuracy of selected genes for PBM. The microarray experiments identified a total of 876 DEGs in PBM, among which 530 were up-regulated and the remaining 346 were down-regulated. Verification of the top 5 up-regulated genes (TYMS, MYBPC1, FUT1, XAGE2, and GREB1L) by qRT-PCR confirmed the up-regulation of MYBPC1 and FUT1. Receiver operating characteristic curve analysis suggested that FUT1 and MYBPC1 up-regulation could be used to predict PBM, with the area under the curve of 0.873 (95%CI=0.735-1.000) and 0.960 (95%CI=0.891-1.000), respectively. FUT1 and MYBPC1 were up-regulated in children with PBM, and could be used as potential biomarkers for PBM.
胰胆管合流异常(PBM)与胆管或胆囊上皮非典型增生及恶性转化的高风险相关。然而,尚未对PBM患儿的基因表达整体变化进行研究。使用10例PBM患儿和15例儿科对照的外周血样本分析全基因组表达。通过微阵列鉴定差异表达基因(DEG)。使用基因本体论和KEGG分析进行生物信息学分析。用qRT-PCR验证PBM中上调基因的前5名。进行受试者工作特征曲线分析以评估所选基因对PBM的预测准确性。微阵列实验在PBM中共鉴定出876个DEG,其中530个上调,其余346个下调。通过qRT-PCR对上调的前5个基因(TYMS、MYBPC1、FUT1、XAGE2和GREB1L)进行验证,证实了MYBPC1和FUT1的上调。受试者工作特征曲线分析表明,FUT1和MYBPC1上调可用于预测PBM,曲线下面积分别为0.873(95%CI=0.735-1.000)和0.960(95%CI=0.891-1.000)。FUT1和MYBPC1在PBM患儿中上调,可作为PBM的潜在生物标志物。